SCHEMBL456513

SCHEMBL456513

CN(C)c1ccc(NNC(N)=S)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.67
GAA P10253 9/20 0.67
ALDH1A1 P00352 7/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
KMT2A Q03164 2/20 0.67
CA2 P00918 2/20 0.51
CA5A P35218 1/20 0.51
GLA P06280 1/20 0.49
MAOA P21397 1/20 0.47
LMNA P02545 2/20 0.44
ALOX12 P18054 1/20 0.44
CA1 P00915 1/20 0.43
HSD17B10 Q99714 2/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
POLB P06746 1/20 0.42
ADRA2A P08913 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ADRA2B P18089 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL667827 0.83 CA2 (0.67) MAPTGAAALDH1A1KMT2ACA2
SCHEMBL6926083 0.80 MAPT (1.00) MAPTGAAALDH1A1SMN1; SMN2KMT2A
SCHEMBL1520890 0.78 GAA (0.61) MAPTGAAALDH1A1SMN1; SMN2CA2
SCHEMBL28916359 0.77 CA2 (0.60) MAPTGAAALDH1A1SMN1; SMN2KMT2A
SCHEMBL11634151 0.77 CA2 (0.47) MAPTGAAALDH1A1SMN1; SMN2KMT2A
SCHEMBL9725156 0.76 MAPT (0.78) MAPTGAAALDH1A1SMN1; SMN2KMT2A
SCHEMBL22924451 0.74 ALDH1A1 (0.55) MAPTGAAALDH1A1SMN1; SMN2KMT2A
SCHEMBL6680813 0.74 CA2 (0.56) MAPTGAAALDH1A1KMT2ACA2
SCHEMBL458638 0.74 CA2 (0.56) MAPTGAAALDH1A1SMN1; SMN2KMT2A
SCHEMBL7043304 0.74 GAA (0.64) MAPTGAAALDH1A1CA2CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2240175-B1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY US GOV HEALTH & HUMAN SERV (US) 2013-01-02 EP disclosed
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY ABCC1, ABCB1, ABCC2 MAPT 4584/4885GAA 231/4885ALDH1A1 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.